glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Schematic illustration of monoagonists, dual
Description
These features make GLP-1 RAs an advantageous alternative to rapid-acting insulin for patients inadequately controlled on a long-acting basal insulin
p = 0.02) (Fig
Although medications alone can help reduce the number on the scale, this four-level approach to obesity care management is integral to long-term success
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58
* Note: All prices are current at the time of publishing, and come from Optum Perks, a free coupon search engine
